Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inotersen: First Global Approval.

Drugs - 1 Sept 2018

Keam Susan J

Abstract excerpt

Ionis Pharmaceuticals and Akcea Therapeutics have developed inotersen (Tegsedi™), an antisense oligonucleotide inhibitor of mutant and wild-type human transthyretin (TTR), for the treatment of hereditary transthyretin amyloidosis (hATTR). Mutation of the TTR gene results in accumulation of TTR protein fragments as amyloid deposits throughout the organs in patients with hATTR, including the peripheral nervous...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloid Neuropathies, Familial
Share to Drug Approval
Share to Europe

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Oligonucleotides

Share to Oligonucleotides, Antisense

Share to Polyneuropathies

Share to Prealbumin

Share to Quality of Life

Source

Identifiers

PMID: 30120737
DOI: 10.1007/s40265-018-0968-5

Genes

TTR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inotersen: First Global Approval.PMID 30120737Read ↗

Tegsedi (Inotersen): An Antisense Oligonucleotide Approved for the Treatment of Adult Patients with Hereditary Transthyretin AmyloidosisSemantic proximity Read ↗

Inotersen: new promise for the treatment of hereditary transthyretin amyloidosisSemantic proximity Read ↗

Real-life experience with inotersen in hereditary transthyretin amyloidosis with late-onset phenotype: Data from an early-access program in Italy.Semantic proximity Read ↗

Treating hereditary transthyretin amyloidosis: Present & future challenges.Semantic proximity Read ↗

Canadian Guidelines for Hereditary Transthyretin Amyloidosis Polyneuropathy ManagementSemantic proximity Read ↗

Population Pharmacokinetic-Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis.Semantic proximity Read ↗

RNA Targeting and Gene Editing Strategies for Transthyretin AmyloidosisSemantic proximity Read ↗

Drug and Gene Therapy for Treating Variant Transthyretin Amyloidosis (ATTRv) Neuropathy.Semantic proximity Read ↗

Hereditary transthyretin amyloidosis in the era of RNA interference, antisense oligonucleotide, and CRISPR-Cas9 treatmentsSemantic proximity Read ↗

Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotidesSemantic proximity Read ↗

Disease-Modifying Treatments for Transthyretin Amyloidosis.Semantic proximity Read ↗

Safety and Efficacy of RNAi Therapy for Transthyretin AmyloidosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.